Search Results 2071-2080 of 19709 for Hemoglobin

  1. Neurology - Clinical trials - Mayo Clinic

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  2. Study of TERN-601 in Adults with Overweight or Obesity - Mayo Clinic

    ... hemoglobin value < 11 g/dL (males) or <10 g/dL (females); Triglycerides > 500 mg/dL (5.7 mmol/L); if participant is on lipid-lowering therapy, must be on ...

  3. A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL; Patients may be transfused or receive erythropoietic treatment to meet this criterion. AST, ALT, and alkaline phosphatase ≤ 2.5 x ...

  4. A Study to Test the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer - Mayo Clinic

    Hemoglobin ≥ 9 g/dL. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); ≤ 3.0 x ULN for patients with Gilbert's syndrome. Aspartate ...

  5. Tight Focus on Blood Sugar Narrows Options for Diabetes Complications - Mayo Clinic News Network

    The study, funded by Mayo Clinic's Clinical and Translational Science Award, found that tight glycemic control (maintenance of a hemoglobin A1c value lower ...

  6. A Study to Evaluate TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Hemoglobin must be ≥ 8 g/dL. (RBC transfusion allowed ≥14 days before assessment);; Absolute neutrophil count (ANC) ≥ 1000 mm^3 (≥ 1.0 × 10^9 /L); value ...

  7. Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study - Mayo Clinic

    - Hemoglobin ≥ 8 g/dL. - Calculated (Calc.) creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault equation: (140 - age) × weight (kg)/(serum ...

  8. A Study Of 177Lu-FAP-2286 In Advanced Solid Tumors - Mayo Clinic

    Hemoglobin ≥ 9 g/dL. b. Hepatic Function: i. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × institutional upper limit of normal ...

  9. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  10. Testing The Use Of The Combination Of Selumetinib And Olaparib Or Selumetinib Alone Targeted Treatment For RAS Pathway Mutant Recurrent Or Persistent Ovarian And Endometrial Cancers, A ComboMATCH Treatment Trial - Mayo Clinic

    - Hemoglobin (Hgb) >= 9.5 g/dL with no blood transfusion in the past 28 days (within 14 days prior to registration) - Platelets >= 100,000/mcl (within 14 ...